AGL 39.50 Decreased By ▼ -0.50 (-1.25%)
AIRLINK 131.70 Increased By ▲ 2.64 (2.05%)
BOP 6.81 Increased By ▲ 0.06 (0.89%)
CNERGY 4.73 Increased By ▲ 0.24 (5.35%)
DCL 8.49 Decreased By ▼ -0.06 (-0.7%)
DFML 41.45 Increased By ▲ 0.63 (1.54%)
DGKC 82.15 Increased By ▲ 1.19 (1.47%)
FCCL 33.25 Increased By ▲ 0.48 (1.46%)
FFBL 72.58 Decreased By ▼ -1.85 (-2.49%)
FFL 12.40 Increased By ▲ 0.66 (5.62%)
HUBC 110.74 Increased By ▲ 1.16 (1.06%)
HUMNL 14.40 Increased By ▲ 0.65 (4.73%)
KEL 5.18 Decreased By ▼ -0.13 (-2.45%)
KOSM 7.65 Decreased By ▼ -0.07 (-0.91%)
MLCF 38.85 Increased By ▲ 0.25 (0.65%)
NBP 63.78 Increased By ▲ 0.27 (0.43%)
OGDC 192.51 Decreased By ▼ -2.18 (-1.12%)
PAEL 25.60 Decreased By ▼ -0.11 (-0.43%)
PIBTL 7.37 Decreased By ▼ -0.02 (-0.27%)
PPL 153.85 Decreased By ▼ -1.60 (-1.03%)
PRL 25.85 Increased By ▲ 0.06 (0.23%)
PTC 17.75 Increased By ▲ 0.25 (1.43%)
SEARL 82.10 Increased By ▲ 3.45 (4.39%)
TELE 7.80 Decreased By ▼ -0.06 (-0.76%)
TOMCL 33.49 Decreased By ▼ -0.24 (-0.71%)
TPLP 8.50 Increased By ▲ 0.10 (1.19%)
TREET 16.60 Increased By ▲ 0.33 (2.03%)
TRG 57.49 Decreased By ▼ -0.73 (-1.25%)
UNITY 27.61 Increased By ▲ 0.12 (0.44%)
WTL 1.37 Decreased By ▼ -0.02 (-1.44%)
BR100 10,495 Increased By 50 (0.48%)
BR30 31,202 Increased By 12.3 (0.04%)
KSE100 98,080 Increased By 281.6 (0.29%)
KSE30 30,559 Increased By 78 (0.26%)

Corcept Therapeutics Inc on Friday said it plans an initial public offering of 5 million shares at an estimated price of $15 to $17 per share.
The company, which makes drugs to treat severe psychiatric and neurological diseases, disclosed the terms of the proposed IPO in an amended offering document filed with the US Securities and Exchange Commission.
The underwriters, led by Thomas Weisel Partners LLC and Piper Jaffray, will have the option to buy another 750,000 shares from a selling stockholder to cover over-allotments, the company said.
Under the terms, Corcept could raise as much as $85 million based on the high end of the price range.
It plans to use proceeds for clinical trials, research and development, working capital and other general corporate purposes.
The Menlo Park, California-based company added it will not receive any proceeds from the sale of shares by the selling holder.

Copyright Reuters, 2004

Comments

Comments are closed.